Earnings summaries and quarterly performance for Tenon Medical.
Executive leadership at Tenon Medical.
Board of directors at Tenon Medical.
Research analysts who have asked questions during Tenon Medical earnings calls.
Recent press releases and 8-K filings for TNON.
Tenon Medical Reports Record Q3 2025 Revenue and Strategic Product Milestones
TNON
Earnings
Product Launch
M&A
- Tenon Medical reported record revenue of $1.2 million in Q3 2025, marking a 32% increase compared to the same period last year, primarily driven by increased Cadmium procedure volumes and the integration of the CyVantage portfolio.
- The company completed the strategic asset acquisition of CyVantage's Symmetry and Symmetry Plus sacroiliac joint fusion technologies during Q3 2025, which was immediately accretive to revenue and transformed Tenon into a multi-product company.
- Key product developments include the full commercial launch of Cadmium FE and the FDA 510(k) clearance of the Symmetry Plus SI joint fusion system, with an alpha launch for Symmetry Plus anticipated in the coming weeks.
- Tenon ended the quarter with $3.4 million in cash and no debt, and subsequently bolstered its cash position with a $2.85 million pipe financing.
Nov 13, 2025, 9:30 PM
Quarterly earnings call transcripts for Tenon Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more